Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

TitleTwo main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.
Publication TypeJournal Article
Year of Publication2013
AuthorsChigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PMV, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F
JournalBlood
Volume122
Issue15
Pagination2673-82
Date Published2013 Oct 10
ISSN1528-0020
KeywordsCell Transformation, Neoplastic, Chromosomes, Human, Pair 12, Disease Progression, Female, Gene Expression Regulation, Leukemic, Genes, p16, Genome-Wide Association Study, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Trisomy, Tumor Suppressor Protein p53
Abstract

Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.

DOI10.1182/blood-2013-03-489518
Alternate JournalBlood
PubMed ID24004666
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700